Evidence map›Paper›PMID 35577856›Full record

ArticleScientific reports2022

Label-free discrimination of tumorigenesis stages using in vitro prostate cancer bone metastasis model by Raman imaging.

Sumanta Kar, Sharad V Jaswandkar, Kalpana S Katti, Jeon Woong Kang, Peter T C So, Ramasamy Paulmurugan, Dorian Liepmann, Renugopalakrishnan Venkatesan, Dinesh R Katti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Sumanta KarDepartment of Civil, Construction and Environmental Engineering, Center for Engineered Cancer Testbeds, Materials and Nanotechnology Program, North Dakota State University, Fargo, ND, 58108, USA.
Sharad V JaswandkarDepartment of Civil, Construction and Environmental Engineering, Center for Engineered Cancer Testbeds, Materials and Nanotechnology Program, North Dakota State University, Fargo, ND, 58108, USA.
Kalpana S KattiDepartment of Civil, Construction and Environmental Engineering, Center for Engineered Cancer Testbeds, Materials and Nanotechnology Program, North Dakota State University, Fargo, ND, 58108, USA.
Jeon Woong KangLaser Biomedical Research Center, G. R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, MB, 02139, Cambridge, USA.
Peter T C SoLaser Biomedical Research Center, G. R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, MB, 02139, Cambridge, USA.
Ramasamy PaulmuruganCellular Pathway Imaging Laboratory (CPIL), Department of Radiology, Stanford University School of Medicine, 3155 Porter Drive, Suite 2236, Palo Alto, CA, 94304, USA.
Dorian LiepmannDepartment of Bioengineering, University of California, Berkeley, CA, USA.
Renugopalakrishnan VenkatesanBoston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Dinesh R KattiDepartment of Civil, Construction and Environmental Engineering, Center for Engineered Cancer Testbeds, Materials and Nanotechnology Program, North Dakota State University, Fargo, ND, 58108, USA. dinesh.katti@ndsu.edu.
North Dakota State University · USMassachusetts Institute of Technology · USNortheastern University · USStanford University · USUniversity of California, Berkeley · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
Tracking and Evaluation CoreU54GM128729 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI BASSON, MARC D. · 2018 to 2022
$20.3M
Wide-Field Short-Wave Infrared (SWIR) multiphoton (MP) tissue imagingP41EB015871 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SO, PETER T. · 2012 to 2021
$11.3M
NCI NIH HHS P30 CA124435NIBIB NIH HHS P41 EB015871NIGMS NIH HHS U54 GM128729NIH HHS NIH P41-EB015871-33
6 · The paper itself

Abstract

Metastatic prostate cancer colonizes the bone to pave the way for bone metastasis, leading to skeletal complications associated with poor prognosis and morbidity. This study demonstrates the feasibility of Raman imaging to differentiate between cancer cells at different stages of tumorigenesis using a nanoclay-based three-dimensional (3D) bone mimetic in vitro model that mimics prostate cancer bone metastasis. A comprehensive study comparing the classification of as received prostate cancer cells in a two-dimensional (2D) model and cancer cells in a 3D bone mimetic environment was performed over various time intervals using principal component analysis (PCA). Our results showed distinctive spectral differences in Raman imaging between prostate cancer cells and the cells cultured in 3D bone mimetic scaffolds, particularly at 1002, 1261, 1444, and 1654 cm

Indexed as

Bone NeoplasmsProstatic NeoplasmsBone and BonesCarcinogenesisCell Line, TumorCell Transformation, NeoplasticHumansMale

Identifiers

PMID35577856
PMCPMC9110417
OpenAlexW4280548014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.